Mira Pharmaceuticals, Inc. (MIRA) — SEC Filings
Mira Pharmaceuticals, Inc. (MIRA) — 50 SEC filings. Latest: 8-K (Dec 22, 2025). Includes 40 8-K, 5 10-Q, 2 10-K/A.
View Mira Pharmaceuticals, Inc. on SEC EDGAR
Overview
Mira Pharmaceuticals, Inc. (MIRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: MIRA Pharmaceuticals, Inc. reported no revenue for the three and nine months ended September 30, 2025, consistent with its clinical-stage status. The company's net loss attributable to common shareholders significantly widened to $(22,694,494) for the three months ended September 30, 2025, compared
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Mira Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Mira Pharmaceuticals, Inc. (MIRA) has filed 40 8-K, 5 10-Q, 1 DEFA14A, 2 10-K/A, 1 10-K, 1 10-Q/A with the SEC between Aug 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of MIRA's 47 recent filings, 2 were flagged as high-risk, 19 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(22,694,494) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $2,641,539 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Industry Context
The pharmaceutical industry, particularly the clinical-stage segment, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like MIRA Pharmaceuticals rely heavily on external funding to advance their drug candidates through trials. The competitive landscape involves numerous companies vying for market share and investor capital, with success often hinging on breakthrough discoveries and effective clinical trial execution.
Top Tags
8-K (8) · regulatory-filing (7) · pharmaceuticals (7) · corporate-action (6) · address-change (6) · corporate-event (5) · 8-k (4) · acquisition (4) · 10-Q (4) · financials (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss attributable to common shareholders | $(22,694,494) | for the three months ended September 30, 2025, significantly widened from $(2,043,867) in 2024 |
| Deemed dividend | $(21,556,821) | contributed to the increased net loss for the three and nine months ended September 30, 2025 |
| Cash balance | $2,641,539 | as of September 30, 2025, down from $2,832,931 at December 31, 2024 |
| Net cash flows from operating activities | $(3,526,632) | used during the nine months ended September 30, 2025 |
| Marketable equity securities | $4,718,310 | received as partial consideration in the SKNY acquisition |
| Total stockholders' equity | $7,549,354 | as of September 30, 2025, an increase from $2,199,750 at December 31, 2024 |
| Research and development expenses | $1,223,240 | for the nine months ended September 30, 2025, a decrease from $2,444,134 in 2024 |
| Shares of common stock issued and outstanding | 41,876,087 | as of November 11, 2025 |
| Period End Date | 2025-06-30 | Latest reporting period |
| Prior Year Period End Date | 2024-06-30 | Comparison period |
| Year-to-Date Start Date | 2025-01-01 | Current fiscal year |
| Prior Year-to-Date Start Date | 2024-01-01 | Previous fiscal year |
| Reporting Period | Q1 2025 | First quarter of 2025 |
| Filing Date | 2025-05-14 | Date the report was submitted |
| SEC File Number | 001-41765 | Identifies the company's filings with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Mira Pharmaceuticals, Inc. (MIRA)?
Mira Pharmaceuticals, Inc. has 50 recent SEC filings from Aug 2024 to Dec 2025, including 40 8-K, 5 10-Q, 2 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MIRA filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Mira Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mira Pharmaceuticals, Inc. (MIRA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mira Pharmaceuticals, Inc.?
Key financial highlights from Mira Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MIRA?
The investment thesis for MIRA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mira Pharmaceuticals, Inc.?
Executive information for Mira Pharmaceuticals, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Mira Pharmaceuticals, Inc. stock?
Of MIRA's 47 assessed filings, 2 were flagged high-risk, 19 medium-risk, and 26 low-risk.
What are recent predictions and forward guidance from Mira Pharmaceuticals, Inc.?
Forward guidance and predictions for Mira Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.